Dyne Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1560 Trapelo Rd, Waltham, Massachusetts,...Phone Number
(781) 786-8230Website
www.dyne-tx.comRevenue
-Stock Symbol
DYNIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
2
1
1
1
1
About Dyne Therapeutics
Founded in 2018, Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approachesExplore more
Dyne Therapeutics Org Chart
RB
Chief Scientific Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dyne Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Dyne Therapeutics had a recent Job posting/layoffs
Check out if Dyne Therapeutics is spiking on competitors!
Dyne Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Dyne Therapeutics
Earning: See what the market has to say on Dyne Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Dyne Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Dyne Therapeutics launches new products
Funding: Get notified immidiatlly once Dyne Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Dyne Therapeutics
Find 2 more new buyers
Compare Similar Companies to Dyne Therapeutics
Compare insights from companies similar to Dyne Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dyne Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dyne Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dyne Therapeutics.
Dyne Therapeutics financials insights
Gather financial insights about Dyne Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$50M
2020
Other Financing Round
$115M
Stock Offering
$233M
2025
Stock/Share Issuance
$505M
2026
Debt
$50M
Dyne Therapeutics Tech Stack
A closer look at the technologies used by Dyne Therapeutics
See more technologies
Most Recent Scoops
Person-Based
Medical Research, Pharmaceuticals
Open Position
Person-Based
Stake & Stock Ownership, Finance, Tax
Open Position
Open Position
Dyne Therapeutics News & Media
Dyne Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that management is scheduled to participate in the following upcoming investor conferences:Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has granted inducement equity awards to 11 newly hired employees. The awards were made as an inducement material to the newly hired employees’ acceptance of employment with Dyne in accordance with Nasdaq Listing Rule 5635(c)(4).Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
- Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 -Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
- Company’s third program to enter clinical development leveraging FORCE platform with the goal of delivering functional improvement in rare neuromuscular disease -
Read more news
Top Manufacturing Companies
See more top companies
Frequently Asked Questions Regarding Dyne Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2018, Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to musc... Read More
